Entrada Therapeutics, Inc.·4

Mar 3, 6:20 PM ET

WENTWORTH KORY JAMES 4

Research Summary

AI-generated summary

Updated

Entrada (TRDA) CFO Kory Wentworth Receives RSUs; Sell-to-Cover $101K

What Happened
CFO Kory Wentworth received two equity awards on March 1, 2026: 44,600 shares (award at $0.00) and 66,600 derivative shares/awards (also $0.00). To cover minimum statutory withholding, the company automatically sold portions of his shares: 2,939 shares on March 2, 2026 (weighted avg price $11.66) for $34,263 and 5,712 shares on March 3, 2026 (weighted avg price $11.76) for $67,153 — about $101,416 total. The sales were mandatory sell-to-cover transactions, not discretionary trades by the reporting person.

Key Details

  • Transaction dates: March 1, 2026 (awards); March 2, 2026 and March 3, 2026 (automatic sales). Filing date: March 3, 2026.
  • Awarded: 44,600 shares (grant) and 66,600 derivative awards (total 111,200). Both reported at $0.00 acquisition price.
  • Sales: 2,939 shares (WAP $11.66; price range reported 11.17–11.91) and 5,712 shares (WAP $11.76; price range reported 11.22–12.095).
  • Proceeds: ~$34,263 and ~$67,153 respectively (≈ $101,416 total) used to satisfy tax withholding.
  • Shares owned after transaction: not stated in the filing.
  • Notable footnotes: F1 describes RSU vesting (25% each March 1, 2027–2030); F2 confirms the sales were mandatory sell-to-cover; F3/F4 note weighted-average pricing ranges; F5 describes a separate option-style vesting schedule for derivative awards.
  • Timeliness: Filing appears timely (filed March 3 for March 1–3 transactions); no late-filing flag noted.

Context
This is primarily a grant (award) event with routine, automatic sell-to-cover sales to satisfy tax withholding — a common administrative step that does not necessarily signal personal selling intent. The awards include RSU-style and/or derivative awards with multi-year vesting schedules, meaning the recipient only receives the underlying shares as they vest over 2027–2030.